Zogenix Inc. (Nasdaq: ZGNX) narrowed losses for the
fourth quarter to 14 cents per share from 28 cents per share in the
year ago period but the company did not provide guidance for 2015 and
announced plans to sell its Zohydro pain treatment business to Pernix. Shares of the pharmaceutical dropped 43 cents to $1.24.
Zogenix sells Zohydro business
March 11, 2015 at 12:34 PM EDT
